Rani Therapeutics Hldgs (NASDAQ:RANI) has received mostly bullish ratings from analysts in the last quarter, with 5 bullish and 1 somewhat bullish ratings. The average 12-month price target for the stock, according to 6 analysts, is $18.83, representing a 7.38% decrease from the previous average price target of $20.33.